229 related articles for article (PubMed ID: 27460639)
1. Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction.
Li C; Ding L; Sun CW; Wu LC; Zhou D; Pawlik KM; Khodadadi-Jamayran A; Westin E; Goldman FD; Townes TM
Sci Rep; 2016 Jul; 6():30422. PubMed ID: 27460639
[TBL] [Abstract][Full Text] [Related]
2. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 system and its applications in human hematopoietic cells.
Hu X
Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
[TBL] [Abstract][Full Text] [Related]
4. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
5. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
[TBL] [Abstract][Full Text] [Related]
6. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
7. Efficient gene correction of an aberrant splice site in β-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides.
Xiong Z; Xie Y; Yang Y; Xue Y; Wang D; Lin S; Chen D; Lu D; He L; Song B; Yang Y; Sun X
J Cell Mol Med; 2019 Dec; 23(12):8046-8057. PubMed ID: 31631510
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells.
Park S; Gianotti-Sommer A; Molina-Estevez FJ; Vanuytsel K; Skvir N; Leung A; Rozelle SS; Shaikho EM; Weir I; Jiang Z; Luo HY; Chui DHK; Figueiredo MS; Alsultan A; Al-Ali A; Sebastiani P; Steinberg MH; Mostoslavsky G; Murphy GJ
Stem Cell Reports; 2017 Apr; 8(4):1076-1085. PubMed ID: 28111279
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
Hoban MD; Lumaquin D; Kuo CY; Romero Z; Long J; Ho M; Young CS; Mojadidi M; Fitz-Gibbon S; Cooper AR; Lill GR; Urbinati F; Campo-Fernandez B; Bjurstrom CF; Pellegrini M; Hollis RP; Kohn DB
Mol Ther; 2016 Sep; 24(9):1561-9. PubMed ID: 27406980
[TBL] [Abstract][Full Text] [Related]
10. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases.
Sebastiano V; Maeder ML; Angstman JF; Haddad B; Khayter C; Yeo DT; Goodwin MJ; Hawkins JS; Ramirez CL; Batista LF; Artandi SE; Wernig M; Joung JK
Stem Cells; 2011 Nov; 29(11):1717-26. PubMed ID: 21898685
[TBL] [Abstract][Full Text] [Related]
11. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
12. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
13. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
Li C; Wang H; Georgakopoulou A; Gil S; Yannaki E; Lieber A
Mol Ther; 2021 Feb; 29(2):822-837. PubMed ID: 32949495
[TBL] [Abstract][Full Text] [Related]
14. Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.
Wattanapanitch M
Methods Mol Biol; 2021; 2211():193-211. PubMed ID: 33336279
[TBL] [Abstract][Full Text] [Related]
15. Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells.
Niu X; He W; Song B; Ou Z; Fan D; Chen Y; Fan Y; Sun X
J Biol Chem; 2016 Aug; 291(32):16576-85. PubMed ID: 27288406
[TBL] [Abstract][Full Text] [Related]
16. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
17. Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein.
Kagita A; Lung MSY; Xu H; Kita Y; Sasakawa N; Iguchi T; Ono M; Wang XH; Gee P; Hotta A
Stem Cell Reports; 2021 Apr; 16(4):985-996. PubMed ID: 33711268
[TBL] [Abstract][Full Text] [Related]
18. Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors.
Sürün D; Schneider A; Mircetic J; Neumann K; Lansing F; Paszkowski-Rogacz M; Hänchen V; Lee-Kirsch MA; Buchholz F
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32384610
[TBL] [Abstract][Full Text] [Related]
19. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
20. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]